Advertisement
Advertisement
DXCM
DexCom, Inc.
83.45
USDSponsored
+8.91
+11.95%
Jul 31, 15:59 UTC -4
Closed
After-Market
82.74
-0.71
-0.85%
DXCM Earnings Reports
Positive Surprise Ratio
DXCM beat 34 of 43 last estimates.
79%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.36B
/$0.68
Implied change from Q1 26 (Revenue/ EPS)
+4.11%
/-2.86%
Implied change from Q3 25 (Revenue/ EPS)
+12.64%
/+11.48%
DexCom, Inc. earnings per share and revenue
On Jul 30, 2026, DXCM reported earnings of 0.70 USD per share (EPS) for Q1 26, beating the estimate of 0.62 USD, resulting in a 12.38% surprise. Revenue reached 1.31 billion, compared to an expected 1.32 billion, with a -0.58% difference. The market reacted with a +3.02% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 23 analysts forecast an EPS of 0.68 USD, with revenue projected to reach 1.36 billion USD, implying an decrease of -2.86% EPS, and increase of 4.11% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
IQVIA Holdings Inc.
Report Date
Jul 28, 2026 For Q2 26
Estimate
$3.06
Actual
$3.15
Surprise
+2.92%
Penumbra, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.08
Actual
$0.88
Surprise
-18.96%
Glaukos Corporation
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.14
Surprise
+34.85%
Veracyte, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.24
Actual
$0.31
Surprise
+28.15%
Axogen, Inc. Common Stock
Report Date
Jul 29, 2026 For Q2 26
Estimate
$0.12
Actual
$0.12
Surprise
-3.15%
iRadimed Corporation
Report Date
Jul 31, 2026 For Q2 26
Estimate
$0.42
Actual
$0.46
Surprise
+7.38%
Integra LifeSciences Holdings
Report Date
Jul 29, 2026 For Q2 26
Estimate
$0.49
Actual
$0.56
Surprise
+13.57%
Beta Bionics, Inc. Common Stock
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$0.60
Actual
-$0.53
Surprise
+12.77%
enVVeno Medical Corporation Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$4.78
Actual
-$5.37
Surprise
-12.25%
FAQ
What were DexCom, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, DexCom, Inc. reported EPS of $0.70, beating estimates by 12.38%, and revenue of $1.31B, -0.58% below expectations.
How did the market react to DexCom, Inc.'s Q1 2026 earnings?
The stock price moved up 3.02%, changed from $59.55 before the earnings release to $61.35 the day after.
When is DexCom, Inc. expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for DexCom, Inc.'s next earnings report?
Based on 23
analysts, DexCom, Inc. is expected to report EPS of $0.68 and revenue of $1.36B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement